P
Palak Shah
Researcher at New York Medical College
Publications - 153
Citations - 7077
Palak Shah is an academic researcher from New York Medical College. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 27, co-authored 111 publications receiving 5457 citations. Previous affiliations of Palak Shah include University of Michigan & St. Vincent's Health System.
Papers
More filters
Journal ArticleDOI
Knowledge of Genome Sequencing and Trust in Medical Researchers Among Patients of Different Racial and Ethnic Groups With Idiopathic Dilated Cardiomyopathy.
Hanyu Ni,Elizabeth Jordan,Jinwen Cao,Daniel D. Kinnamon,Stephen S. Gottlieb,Mark R. Hofmeyer,Javier Jiménez,Daniel P. Judge,Evan P. Kransdorf,Alanna A. Morris,Anjali T. Owens,Palak Shah,W.H. Wilson Tang,Jessica Wang,Ray E. Hershberger +14 more
TL;DR: In this article , a cross-sectional study conducted by a consortium of 25 US heart failure programs included patients with idiopathic dilated cardiomyopathy defined as left ventricular systolic dysfunction and right ventricular enlargement after excluding usual clinical causes.
Journal ArticleDOI
Central venous access in the pediatric cancer patient—Problems unique to developing countries: 5-year experience at a regional cancer center in Western India
Ravindra Mohan Pandey,A. Patel,Sandip Shah,K. M. Patel,Palak Shah,Shilin N. Shukla,BJ Parikh,Asha Anand,S. S. Talati,Harsha Panchal +9 more
TL;DR: Hickman is the most preferred CVC in pediatric oncology in a developing country as most patients do not afford port and most patients are of low literacy and poor socioeconomic status, reflected in significantly high rates of CVC infection.
Journal ArticleDOI
Avoiding the “set it and forget it mentality”: A need to regularly reassess left ventricular assist device patients for optimal support
Journal ArticleDOI
Aortic vasculature changes following support with a continuous-flow left ventricular assist device: The role of pulsatility
Palak Shah,Francis D. Pagani +1 more
TL;DR: The past decade of durable mechanical circulatory support has been dominated by continuous-flow (CF) left ventricular assist devices (LVADs), and a great deal of uncertainty remains regarding how the human body responds over the long-term to absent or diminished pulsatility.
Journal ArticleDOI
Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention.
Monil Majmundar,Tikal Kansara,Akash Jain,Palak Shah,Priyam Mithawala,Rupak Desai,Priyank Shah,Rajkumar Doshi +7 more
TL;DR: It is demonstrated that cangrelor significantly reduced the rate of the composite outcome of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours and 30 days compared with clopidogrel, with no significant increase in major bleeding.